Patients on GLP-1s: What Clinicians and Users Need to Know Across Populations

What GLP-1 Receptor Agonists Do in the Body

GLP-1 receptor agonists replicate the action of glucagon-like peptide-1, a hormone secreted by L-cells in the ileum after meals. The native hormone has a half-life of roughly 2 minutes. Pharmaceutical modifications (acylation to albumin, amino acid substitutions) extend that half-life to days or even weeks, enabling once-weekly dosing for agents like semaglutide and dulaglutide 1.

These drugs act on at least three organ systems simultaneously. In the pancreas, they amplify glucose-dependent insulin secretion and suppress glucagon. In the hypothalamus, they reduce appetite signaling. In the cardiovascular system, they appear to attenuate inflammation and improve endothelial function. The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in patients with obesity but without diabetes 2. That finding widened the clinical lens: GLP-1s are no longer just diabetes drugs.

The dual GIP/GLP-1 agonist tirzepatide adds glucose-dependent insulinotropic polypeptide activation, which contributed to the 22.5% mean weight loss seen in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose over 72 weeks 3.

Patients with Type 2 Diabetes

GLP-1 receptor agonists occupy a preferred second-line position in the 2024 ADA Standards of Care for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease 4. Metformin remains first-line, but the gap is narrowing.

A1C reductions vary by agent. The SUSTAIN-7 trial showed semaglutide 1.0 mg lowered A1C by 1.8 percentage points versus 1.4 points for dulaglutide 1.5 mg at 40 weeks 5. Tirzepatide at 15 mg produced a 2.07 percentage point A1C reduction in the SURPASS-2 trial (N=1,879), with 86% of participants reaching an A1C below 7% 6.

The cardiovascular story matters most for this group. The LEADER trial (N=9,340) established that liraglutide reduced MACE by 13% and cardiovascular death by 22% over 3.8 years in patients with type 2 diabetes at high cardiovascular risk 7. SUSTAIN-6 (N=3,297) showed semaglutide cut MACE by 26%, driven largely by a 39% reduction in nonfatal stroke 8.

Dr. Vanita Aroda, then chair of the ADA's pharmacologic treatment section, stated: "For patients with type 2 diabetes and atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit should be considered independently of A1C" 4.

Hypoglycemia risk remains low with GLP-1 monotherapy because insulin secretion is glucose-dependent. The risk rises only when combined with sulfonylureas or exogenous insulin. Dose reduction of the sulfonylurea by 50% at GLP-1 initiation is standard practice 4.

Older Adults on GLP-1 Therapy

Patients aged 65 and older face a specific trade-off. They benefit from the cardiometabolic improvements, but they are disproportionately vulnerable to the loss of lean muscle mass that accompanies rapid weight loss on GLP-1 agonists.

In the STEP 1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. Body composition analysis showed that approximately 39% of the weight lost was lean mass 9. For a 72-year-old with borderline sarcopenia, that ratio is clinically dangerous.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic treatment of obesity recommends that older adults on GLP-1 agonists receive structured resistance exercise at least twice weekly and consume 1.0 to 1.2 g of protein per kilogram of body weight daily to attenuate muscle loss 10. These are not optional add-ons. They are safety requirements.

Renal dose adjustment adds another layer. Liraglutide requires no renal adjustment, but GI side effects can cause dehydration that worsens existing kidney disease. The FLOW trial (N=3,533) demonstrated that semaglutide 1.0 mg reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and CKD 11. That benefit extends to older patients, though monitoring serum creatinine and hydration status is non-negotiable.

Falls represent the downstream concern. A meta-analysis published in Diabetes, Obesity and Metabolism found that GLP-1 RA-associated weight loss in adults over 60 was linked to improved mobility scores but did not assess fracture outcomes independently 12. Until fracture data matures, the clinical default should be: prescribe the GLP-1, mandate the exercise, monitor grip strength, and check vitamin D levels at baseline.

Gastroparesis-like symptoms also appear more frequently in older populations. Slower gastric emptying from aging compounds the GLP-1 mechanism. If nausea persists beyond 8 weeks at a given dose, the 2024 AGA guideline recommends holding dose escalation rather than adding antiemetics 13.

Women on GLP-1 Medications

Reproductive-age women on GLP-1 agonists face a pharmacokinetic interaction that receives too little attention. GLP-1 receptor agonists delay gastric emptying, which can reduce the absorption of oral contraceptives. The FDA-approved labeling for semaglutide notes this interaction and recommends that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method during GLP-1 treatment 14.

This is not theoretical. Post-marketing surveillance data and social media reports of so-called "Ozempic babies" reflect real-world unintended pregnancies in women who relied on oral contraceptives while taking semaglutide. The mechanism is straightforward: delayed gastric transit lowers peak plasma concentrations of ethinyl estradiol and levonorgestrel.

Weight loss itself can restore ovulation in women with PCOS. A 5 to 10% reduction in body weight improves menstrual regularity in approximately 50% of anovulatory women with PCOS 15. The combination of restored fertility and impaired oral contraceptive absorption creates a narrow but real window of unintended pregnancy risk.

For women in menopause or perimenopause, GLP-1 therapy intersects with bone health. Estrogen decline accelerates bone resorption; rapid weight loss compounds the problem. The STEP 4 extension analysis showed that bone mineral density (BMD) at the lumbar spine did not decline significantly with continued semaglutide use, but the study was not powered for fracture endpoints 16. DEXA monitoring at baseline and 12 months is reasonable for postmenopausal women starting a GLP-1 agonist, especially those with a T-score between -1.0 and -2.5.

Dr. Ania Jastreboff, lead investigator of the SURMOUNT program, has noted: "The benefits of GLP-1 and dual incretin agonists extend across sex, but we need sex-specific data on lean mass preservation, bone density, and reproductive outcomes to guide clinical decision-making" 3.

GLP-1 Agonists and Pregnancy

Every GLP-1 receptor agonist currently approved in the United States carries a recommendation to discontinue before planned conception. The FDA labeling for semaglutide states that the drug should be stopped at least 2 months prior to a planned pregnancy based on its long half-life of approximately 7 days 14. Liraglutide, with a shorter half-life of 13 hours, requires a 1-month washout. Tirzepatide's labeling recommends the same 2-month window as semaglutide.

Animal data drives these restrictions. In reproductive toxicology studies, semaglutide caused embryofetal lethality, structural abnormalities, and growth retardation in rats and rabbits at exposures below the maximum recommended human dose 14. No controlled human pregnancy data exist, and none will exist for ethical reasons. The precautionary approach is absolute.

For women with type 2 diabetes who become pregnant, the ADA recommends transitioning to insulin as the primary glucose-lowering therapy. Metformin may be continued in certain cases, but GLP-1 agonists, SGLT2 inhibitors, and most other non-insulin agents should be stopped 17.

Gestational diabetes, which affects approximately 6 to 9% of pregnancies in the United States, is managed with medical nutrition therapy, blood glucose monitoring, and insulin when targets are not met 17. GLP-1 agonists have no role in gestational diabetes management.

The timeline matters. Women who lose significant weight on a GLP-1 agonist and then conceive within weeks of stopping may still have drug exposure during the critical embryogenesis period (weeks 3 through 8 post-conception). A negative pregnancy test at GLP-1 discontinuation does not guarantee safety if conception occurs before the drug has fully cleared. For semaglutide, five half-lives (35 days) are needed to achieve greater than 97% elimination.

Monitoring and Safety Across All Patient Groups

Gastrointestinal side effects are the most common reason for discontinuation across every population. In STEP 1, nausea occurred in 44% of semaglutide-treated patients versus 17% on placebo, though most events were mild to moderate and resolved within 8 to 12 weeks 9.

Pancreatitis risk has been debated since the first GLP-1 approvals. A 2023 meta-analysis of 36 randomized controlled trials (N=61,614) found no statistically significant increase in acute pancreatitis with GLP-1 receptor agonists (OR 1.02 to 95% CI 0.74 to 1.41) 18. Clinical guidelines still recommend avoiding GLP-1s in patients with a personal history of pancreatitis.

Thyroid C-cell tumors (medullary thyroid carcinoma) carry a boxed warning based on rodent data. Rats exposed to liraglutide and semaglutide developed C-cell hyperplasia and carcinoma at clinically relevant exposures. Human relevance remains uncertain because human thyroid C-cells express far fewer GLP-1 receptors than rat C-cells 1. GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Gallbladder events increase with rapid weight loss on any intervention. In the STEP trials, cholelithiasis occurred in 1.6% of semaglutide-treated patients versus 0.7% on placebo 9. Patients should report right upper quadrant pain promptly.

Baseline labs before starting a GLP-1 agonist should include A1C, fasting glucose, lipid panel, renal function (eGFR, serum creatinine), hepatic function, lipase, and calcitonin (if medullary thyroid carcinoma risk factors exist). Repeat A1C at 3 months and every 6 months thereafter. Weight should be tracked monthly during titration and quarterly at maintenance dose.

When to Start, Adjust, or Stop a GLP-1

Initiation criteria differ by indication. For type 2 diabetes, the ADA recommends GLP-1 agonists as first injectable therapy for patients not at A1C goal on metformin, particularly those with ASCVD, heart failure, or CKD 4. For obesity without diabetes, the Endocrine Society recommends pharmacotherapy for patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity 10.

Dose titration should follow label-specified intervals. Semaglutide for obesity (Wegovy) starts at 0.25 mg weekly for 4 weeks, increases to 0.5 mg, then 1.0 mg, 1.7 mg, and 2.4 mg at 4-week intervals. Skipping titration steps increases nausea and dropout. If a patient cannot tolerate a dose increase after two attempts separated by 4 weeks, the previous tolerated dose becomes the maintenance dose.

Discontinuation triggers include pregnancy planning (stop 2 months before for semaglutide), persistent severe GI symptoms unresponsive to dose reduction, confirmed pancreatitis, or suspected medullary thyroid carcinoma. Weight regain after discontinuation is well-documented: the STEP 1 extension trial showed that participants regained two-thirds of lost weight within 1 year of stopping semaglutide 19. This supports long-term or indefinite treatment for eligible patients, with periodic reassessment of risk-benefit every 12 months.

For patients aged 65 and older starting semaglutide at 2.4 mg target dose, measure handgrip strength and gait speed at baseline using the SARC-F screening tool and repeat at 6-month intervals throughout treatment 10.